384 related articles for article (PubMed ID: 30192088)
1. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis.
Carbon M; Kane JM; Leucht S; Correll CU
World Psychiatry; 2018 Oct; 17(3):330-340. PubMed ID: 30192088
[TBL] [Abstract][Full Text] [Related]
2. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis.
Carbon M; Hsieh CH; Kane JM; Correll CU
J Clin Psychiatry; 2017 Mar; 78(3):e264-e278. PubMed ID: 28146614
[TBL] [Abstract][Full Text] [Related]
3. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study.
Gründer G; Heinze M; Cordes J; Mühlbauer B; Juckel G; Schulz C; Rüther E; Timm J;
Lancet Psychiatry; 2016 Aug; 3(8):717-729. PubMed ID: 27265548
[TBL] [Abstract][Full Text] [Related]
4. Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis.
O'Brien A
Int J Geriatr Psychiatry; 2016 Jul; 31(7):683-93. PubMed ID: 26679687
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of the efficacy of second-generation antipsychotics.
Davis JM; Chen N; Glick ID
Arch Gen Psychiatry; 2003 Jun; 60(6):553-64. PubMed ID: 12796218
[TBL] [Abstract][Full Text] [Related]
6. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review.
Correll CU; Kane JM
J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):647-56. PubMed ID: 17979584
[TBL] [Abstract][Full Text] [Related]
7. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.
Naber D; Lambert M
CNS Drugs; 2009 Aug; 23(8):649-59. PubMed ID: 19594194
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis.
Zhang JP; Gallego JA; Robinson DG; Malhotra AK; Kane JM; Correll CU
Int J Neuropsychopharmacol; 2013 Jul; 16(6):1205-18. PubMed ID: 23199972
[TBL] [Abstract][Full Text] [Related]
9. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics.
Kishimoto T; Agarwal V; Kishi T; Leucht S; Kane JM; Correll CU
Mol Psychiatry; 2013 Jan; 18(1):53-66. PubMed ID: 22124274
[TBL] [Abstract][Full Text] [Related]
10. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients.
Woerner MG; Correll CU; Alvir JM; Greenwald B; Delman H; Kane JM
Neuropsychopharmacology; 2011 Jul; 36(8):1738-46. PubMed ID: 21508932
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
[TBL] [Abstract][Full Text] [Related]
12. Tardive dyskinesia in a South Asian population with first episode psychosis treated with antipsychotics.
Adam UU; Husain N; Haddad PM; Munshi T; Tariq F; Naeem F; Chaudhry IB
Neuropsychiatr Dis Treat; 2014; 10():1953-9. PubMed ID: 25342903
[TBL] [Abstract][Full Text] [Related]
13. Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies.
Masuda T; Misawa F; Takase M; Kane JM; Correll CU
JAMA Psychiatry; 2019 Oct; 76(10):1052-1062. PubMed ID: 31365048
[TBL] [Abstract][Full Text] [Related]
14. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons.
Kishimoto T; Hagi K; Nitta M; Kane JM; Correll CU
World Psychiatry; 2019 Jun; 18(2):208-224. PubMed ID: 31059621
[TBL] [Abstract][Full Text] [Related]
16. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V.
van Harten PN; Hoek HW; Matroos GE; van Os J
J Clin Psychiatry; 2006 Dec; 67(12):1920-7. PubMed ID: 17194270
[TBL] [Abstract][Full Text] [Related]
17. Tardive Dyskinesia and Long-Acting Injectable Antipsychotics: Analyses Based on a Spontaneous Reporting System Database in Japan.
Misawa F; Fujii Y; Takeuchi H
J Clin Psychiatry; 2022 Aug; 83(5):. PubMed ID: 35921512
[No Abstract] [Full Text] [Related]
18. Clinical risk factors for the development of tardive dyskinesia.
Solmi M; Pigato G; Kane JM; Correll CU
J Neurol Sci; 2018 Jun; 389():21-27. PubMed ID: 29439776
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis.
Hartling L; Abou-Setta AM; Dursun S; Mousavi SS; Pasichnyk D; Newton AS
Ann Intern Med; 2012 Oct; 157(7):498-511. PubMed ID: 22893011
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
